Trials / Terminated
TerminatedNCT01108458
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- George Albert Fisher · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2 study combining pertuzumab with erlotinib for patients with gemcitabine refractory pancreatic adenocarcinoma
Detailed description
A single-institution, single-arm phase 2 study investigating pertuzumab and erlotinib as a palliative regimen in the treatment of locally-advanced or metastatic pancreatic adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pertuzumab | iv, 840 mg, 420 mg |
| DRUG | Erlotinib | PO, 150 mg |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2010-11-01
- Completion
- 2011-03-01
- First posted
- 2010-04-22
- Last updated
- 2017-03-03
- Results posted
- 2017-03-03
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01108458. Inclusion in this directory is not an endorsement.